论文部分内容阅读
过去几年,美国的药品短缺现象愈演愈烈,其中非专利的仿制药短缺尤为严重。生产利润微薄、生产企业数目有限、全球性需求增加,以及上市审批耗时漫长等等原因造成了仿制药持续短缺。美国食品与药品管理局、美国临床肿瘤学会,乃至美国国会都陆续出台了一系列对策,探讨药品短缺的根源并试图寻求解决办法。虽然替代药物可以在短期内缓解环境药品短缺的压力,然而有关药品短缺给患者个人带来的安全威胁却尚不明确。研究人员就儿童白血病治疗药品短缺给患者带来的影响进行了探讨……
Over the past few years, the drug shortage in the United States has been intensifying, with the generic shortage of generic drugs particularly serious. Production margins are meager, the number of manufacturing enterprises is limited, global demand increases, and listing approval takes a long time and so on, which causes the sustained shortage of generic drugs. The United States Food and Drug Administration, the American Society of Clinical Oncology and even the US Congress have issued a series of measures to explore the root causes of drug shortage and try to find a solution. Although alternative medicines can relieve the pressure of shortages of environmental drugs in the short term, the security threats posed by the shortage of medicines to individual patients are not yet clear. Researchers explored the impact of drug shortage on the treatment of childhood leukemia on patients ...